MRKMerck Sharp & Dohme LLCRunning, no new patients
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Bladder Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 230 (planned)
- Started
- Mar 28, 2024
- Main results expected
- Apr 23, 2027
- Fully finished
- Oct 20, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adjuvant Cohort: Disease Free Survival (DFS)
Measured over: Up to approximately 28 months
Perioperative Cohort: Number of Participants Who Experience an Adverse Event (AE)
Measured over: Up to approximately 19 months
Perioperative Cohort: Number of Participants Who Discontinue Study Treatment Due to AE
Measured over: Up to approximately 16 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06305767 · record last updated 2026-01-13 · checked 2026-11-09 15:47 UTC